



Clinical trial results:

EMPACT-MI: A streamlined, multicentre, randomised, parallel group, double-blind placebo-controlled superiority trial to evaluate the effect of EMPagliflozin on hospitalisation for heart failure and mortality in patients with aCuTe Myocardial Infarction

Summary

| | |
|--------------------------|-------------------------|
| EudraCT number | 2019-001037-13 |
| Trial protocol | DE HU PL NL BG FR DK ES |
| Global end of trial date | 05 November 2023 |

Results information

| | |
|--------------------------------|------------------|
| Result version number | v1 (current) |
| This version publication date | 20 November 2024 |
| First version publication date | 20 November 2024 |

Trial information

Trial identification

| | |
|-----------------------|-----------|
| Sponsor protocol code | 1245-0202 |
|-----------------------|-----------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT04509674 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|--|
| Sponsor organisation name | Boehringer Ingelheim |
| Sponsor organisation address | Binger Strasse 173, Ingelheim am Rhein, Germany, 55216 |
| Public contact | Boehringer Ingelheim, Call Center, Boehringer Ingelheim, 001 18002430127, clintriage.rdg@boehringer-ingelheim.com |
| Scientific contact | Boehringer Ingelheim, Call Center, Boehringer Ingelheim, 001 18002430127, clintriage.rdg@boehringer-ingelheim.com |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|------------------|
| Analysis stage | Final |
| Date of interim/final analysis | 29 November 2023 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 05 November 2023 |
| Global end of trial reached? | Yes |
| Global end of trial date | 05 November 2023 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

The main objective of this event-driven trial was to demonstrate the superiority of empagliflozin 10 mg once daily versus placebo, in addition to standard of care, for the reduction of the composite endpoint of time to first hospitalisation for heart failure (HHF) or all-cause mortality in high-risk patients hospitalised for acute myocardial infarction (MI).

Protection of trial subjects:

Only subjects that met all the study inclusion and none of the exclusion criteria were to be entered in the study. All subjects were free to withdraw from the clinical trial at any time for any reason given. Close monitoring of all subjects was adhered to throughout the trial conduct. Rescue medication was allowed for all subjects as required.

Background therapy: -

Evidence for comparator: -

| | |
|---|------------------|
| Actual start date of recruitment | 16 December 2020 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | Yes |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|-------------------------|
| Country: Number of subjects enrolled | Argentina: 223 |
| Country: Number of subjects enrolled | Australia: 41 |
| Country: Number of subjects enrolled | Brazil: 359 |
| Country: Number of subjects enrolled | Bulgaria: 422 |
| Country: Number of subjects enrolled | Canada: 359 |
| Country: Number of subjects enrolled | China: 215 |
| Country: Number of subjects enrolled | Denmark: 42 |
| Country: Number of subjects enrolled | France: 130 |
| Country: Number of subjects enrolled | Germany: 234 |
| Country: Number of subjects enrolled | Hungary: 253 |
| Country: Number of subjects enrolled | India: 221 |
| Country: Number of subjects enrolled | Israel: 403 |
| Country: Number of subjects enrolled | Japan: 264 |
| Country: Number of subjects enrolled | Korea, Republic of: 85 |
| Country: Number of subjects enrolled | Netherlands: 229 |
| Country: Number of subjects enrolled | Poland: 824 |
| Country: Number of subjects enrolled | Romania: 868 |
| Country: Number of subjects enrolled | Russian Federation: 112 |

| | |
|--------------------------------------|--------------------|
| Country: Number of subjects enrolled | Serbia: 379 |
| Country: Number of subjects enrolled | Spain: 46 |
| Country: Number of subjects enrolled | Ukraine: 373 |
| Country: Number of subjects enrolled | United States: 528 |
| Worldwide total number of subjects | 6610 |
| EEA total number of subjects | 3048 |

Notes:

Subjects enrolled per age group

| | |
|---|------|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 3308 |
| From 65 to 84 years | 3189 |
| 85 years and over | 113 |

Subject disposition

Recruitment

Recruitment details:

Randomised, placebo-controlled, double-blind, parallel-group trial in acute myocardial infarction (MI) hospitalised patients with high-risk for subsequent hospitalization for heart failure (HHF) and mortality. Patients were treated and remained in the trial until approximately a total number of 532 had primary endpoint events (i.e. event driven).

Pre-assignment

Screening details:

All patients were screened for eligibility prior to participation in the trial. Patients attended a specialist site to ensure that they strictly met all inclusion and none of the exclusion criteria. One patient was randomised in error after death (i.e. mis-randomization) and was excluded from the randomised set.

Period 1

| | |
|------------------------------|---|
| Period 1 title | Overall Study (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Subject, Investigator, Monitor, Carer, Data analyst, Assessor |

Blinding implementation details:

Patients, investigators, and everyone involved in trial conduct or analysis or with any other interest in this double-blind trial remained blinded to the randomised treatment assignments until after database lock.

Arms

| | |
|------------------------------|---------|
| Are arms mutually exclusive? | Yes |
| Arm title | Placebo |

Arm description:

Patients with an acute myocardial infarction event took, on top of standard of care, one placebo matching-empagliflozin 10 milligrams (mg) film-coated tablet, orally, once daily, at the same time every morning, with a glass of water.

| | |
|--|--------------------------------------|
| Arm type | Placebo |
| Investigational medicinal product name | Placebo matching empagliflozin 10 mg |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Film-coated tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Patients received, on top of standard of care, one placebo matching-empagliflozin 10 milligrams (mg) film-coated tablet, orally, once daily, at the same time every morning, with a glass of water.

| | |
|------------------|---------------------|
| Arm title | Empagliflozin 10 mg |
|------------------|---------------------|

Arm description:

Patients with an acute myocardial infarction event took, on top of standard of care, one empagliflozin (Jardiance®) 10 milligrams (mg) film-coated tablet, orally, once daily, at the same time every morning, with a glass of water.

| | |
|--|--------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Empagliflozin |
| Investigational medicinal product code | |
| Other name | Jardiance® |
| Pharmaceutical forms | Film-coated tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Patients received on top of standard of care, one empagliflozin (Jardiance®) 10 milligrams (mg) film-

coated tablet, orally, once daily, at the same time every morning, with a glass of water.

| Number of subjects in period 1^[1] | Placebo | Empagliflozin 10 mg |
|---|---------|---------------------|
| Started | 3262 | 3260 |
| Treated | 3229 | 3234 |
| Completed | 2513 | 2550 |
| Not completed | 749 | 710 |
| Patient refusal to continue, not due to AE | 452 | 418 |
| Other reason than listed | 106 | 95 |
| Adverse event, serious fatal event | 11 | 4 |
| Lost to follow-up | 31 | 39 |
| Not treated | 33 | 26 |
| Protocol deviation | 9 | 10 |
| Adverse event, non-fatal event | 107 | 118 |

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: Out of the 6610 subjects enrolled, 6522 were randomised to a treatment.

Baseline characteristics

Reporting groups

| | |
|---|---------------------|
| Reporting group title | Placebo |
| Reporting group description: | |
| Patients with an acute myocardial infarction event took, on top of standard of care, one placebo matching-empagliflozin 10 milligrams (mg) film-coated tablet, orally, once daily, at the same time every morning, with a glass of water. | |
| Reporting group title | Empagliflozin 10 mg |
| Reporting group description: | |
| Patients with an acute myocardial infarction event took, on top of standard of care, one empagliflozin (Jardiance®) 10 milligrams (mg) film-coated tablet, orally, once daily, at the same time every morning, with a glass of water. | |

| Reporting group values | Placebo | Empagliflozin 10 mg | Total |
|---|---------|---------------------|-------|
| Number of subjects | 3262 | 3260 | 6522 |
| Age categorical | | | |
| Randomised set (RS): All randomised patients, whether treated or not. | | | |
| Units: Patients | | | |
| In utero | 0 | 0 | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 0 | 0 | 0 |
| Children (2-11 years) | 0 | 0 | 0 |
| Adolescents (12-17 years) | 0 | 0 | 0 |
| Adults (18-64 years) | 1623 | 1639 | 3262 |
| From 65-84 years | 1593 | 1556 | 3149 |
| 85 years and over | 46 | 65 | 111 |
| Age Continuous | | | |
| Randomised set (RS): All randomised patients, whether treated or not. | | | |
| Units: years | | | |
| arithmetic mean | 63.7 | 63.6 | |
| standard deviation | ± 10.8 | ± 11.0 | - |
| Sex: Female, Male | | | |
| Randomised set (RS): All randomised patients, whether treated or not. | | | |
| Units: Patients | | | |
| Female | 813 | 812 | 1625 |
| Male | 2449 | 2448 | 4897 |
| Race/Ethnicity, Customized | | | |
| Randomised set (RS): All randomised patients, whether treated or not. | | | |
| Units: Subjects | | | |
| White | 2721 | 2730 | 5451 |
| Black/African-American | 48 | 44 | 92 |
| Asian | 413 | 421 | 834 |
| Other, including mixed race | 7 | 9 | 16 |
| Missing | 73 | 56 | 129 |
| Ethnicity (NIH/OMB) | | | |
| Randomised set (RS): All randomised patients, whether treated or not. | | | |
| Units: Subjects | | | |

| | | | |
|-------------------------|------|------|------|
| Hispanic or Latino | 331 | 338 | 669 |
| Not Hispanic or Latino | 2859 | 2866 | 5725 |
| Unknown or Not Reported | 72 | 56 | 128 |

End points

End points reporting groups

| | |
|---|---------------------|
| Reporting group title | Placebo |
| Reporting group description: Patients with an acute myocardial infarction event took, on top of standard of care, one placebo matching-empagliflozin 10 milligrams (mg) film-coated tablet, orally, once daily, at the same time every morning, with a glass of water. | |
| Reporting group title | Empagliflozin 10 mg |
| Reporting group description: Patients with an acute myocardial infarction event took, on top of standard of care, one empagliflozin (Jardiance®) 10 milligrams (mg) film-coated tablet, orally, once daily, at the same time every morning, with a glass of water. | |

Primary: Composite of time to first heart failure hospitalisation or all-cause mortality

| | |
|--|---|
| End point title | Composite of time to first heart failure hospitalisation or all-cause mortality |
| End point description: Incidence rate of the first occurrence of hospitalisation for heart failure (HHF) or death, whichever earliest, is reported. Median time-to-event was not estimable due to insufficient events being experienced. The incidence rate was calculated as: the number of patients with an event for hospitalization for heart failure or death by treatment group during time at risk divided by the total time patients were at risk in that treatment group multiplied by 100 (per 100 Pt-years, Pt as abbreviation of patient). The analysis was performed on the randomised set (RS) which contained all randomised patients, whether treated or not. | |
| End point type | Primary |
| End point timeframe: From randomisation or first study drug administration (if randomisation occurred after first drug administration), until individual day of trial completion. Up to 1004 days. | |

| End point values | Placebo | Empagliflozin 10 mg | | |
|--|---------------------|---------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 3262 | 3260 | | |
| Units: Pt with events/100 pt-years at risk | | | | |
| number (confidence interval 95%) | 6.58 (5.86 to 7.35) | 5.85 (5.17 to 6.57) | | |

Statistical analyses

| | |
|--|------------------------|
| Statistical analysis title | Statistical analysis 1 |
| Statistical analysis description: The primary endpoint was analysed using a Cox proportional hazards model with treatment, type-2 diabetes at baseline, geographical region, age at baseline, estimated glomerular filtration rate at | |

baseline, left ventricular ejection fraction at baseline, persistent or permanent atrial fibrillation at baseline, prior myocardial infarction at baseline, peripheral artery disease at baseline and smoking at baseline as covariates.

| | |
|---|-------------------------------|
| Comparison groups | Placebo v Empagliflozin 10 mg |
| Number of subjects included in analysis | 6522 |
| Analysis specification | Pre-specified |
| Analysis type | superiority ^[1] |
| P-value | = 0.2061 |
| Method | Regression, Cox |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 0.9 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.76 |
| upper limit | 1.06 |

Notes:

[1] - Null hypothesis: there is no difference regarding the risk of the endpoint in question between empagliflozin and placebo.

$p \leq 0.05$ required for testing of subsequent key secondary endpoint hypotheses

Results are presented as Empagliflozin vs. Placebo.

Secondary: Key secondary endpoint - Total number of non-elective cardiovascular (CV) hospitalisations or all-cause mortality

| | |
|-----------------|---|
| End point title | Key secondary endpoint - Total number of non-elective cardiovascular (CV) hospitalisations or all-cause mortality |
|-----------------|---|

End point description:

The total number of non-elective cardiovascular (CV) hospitalisations or all-cause mortality is reported using the adjusted event rate.

The adjusted event rate is based on a negative binomial model adjusted for treatment and type-2 diabetes at baseline, geographical region, age at baseline, estimated glomerular filtration rate at baseline, left ventricular ejection fraction at baseline, persistent or permanent atrial fibrillation at baseline, prior myocardial infarction at baseline, peripheral artery disease at baseline and smoking at baseline as covariates. The log(observation time) was used as an offset variable.

The analysis was performed on the randomised set (RS) which contained all randomised patients, whether treated or not.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From randomisation or first study drug administration (if randomisation occurred after first drug administration), until individual day of trial completion. Up to 1004 days.

| End point values | Placebo | Empagliflozin 10 mg | | |
|---|------------------------|------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 3262 | 3260 | | |
| Units: Events/100 patient-years at risk | | | | |
| number (confidence interval 95%) | 16.90 (15.10 to 18.92) | 15.52 (13.82 to 17.43) | | |

Statistical analyses

| | |
|---|-------------------------------|
| Statistical analysis title | Statistical analysis 1 |
| Statistical analysis description: | |
| The statistical model used was a negative binomial model, including factors for treatment and type-2 diabetes at baseline, geographical region, age at baseline, estimated glomerular filtration rate at baseline, left ventricular ejection fraction at baseline, persistent or permanent atrial fibrillation at baseline, prior myocardial infarction at baseline, peripheral artery disease at baseline and smoking at baseline as covariates. The log(observation time) was used as an offset variable. | |
| Comparison groups | Placebo v Empagliflozin 10 mg |
| Number of subjects included in analysis | 6522 |
| Analysis specification | Pre-specified |
| Analysis type | other ^[2] |
| P-value | = 0.2867 |
| Method | Negative binomial regression |
| Parameter estimate | Adjusted event rate ratio |
| Point estimate | 0.92 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.78 |
| upper limit | 1.07 |

Notes:

[2] - Results are presented as Empagliflozin vs. Placebo.

Secondary: Key secondary endpoint - Total number of hospitalisations for heart failure (HHF) or all-cause mortality

| | |
|-----------------|--|
| End point title | Key secondary endpoint - Total number of hospitalisations for heart failure (HHF) or all-cause mortality |
|-----------------|--|

End point description:

The total number of hospitalisations for heart failure (HHF) or all-cause mortality is reported using the adjusted event rate.

The adjusted event rate is based on a negative binomial model adjusted for treatment and type-2 diabetes at baseline, geographical region, age at baseline, estimated glomerular filtration rate at baseline, left ventricular ejection fraction at baseline, persistent or permanent atrial fibrillation at baseline, prior myocardial infarction at baseline, peripheral artery disease at baseline and smoking at baseline as covariates. The log(observation time) was used as an offset variable.

The analysis was performed on the randomised set (RS) which contained all randomised patients, whether treated or not.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From randomisation or first study drug administration (if randomisation occurred after first drug administration), until individual day of trial completion. Up to 1004 days.

| | | | | |
|---|---------------------|---------------------|--|--|
| End point values | Placebo | Empagliflozin 10 mg | | |
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 3262 | 3260 | | |
| Units: Events/100 patient-years at risk | | | | |
| number (confidence interval 95%) | 8.25 (6.92 to 9.83) | 7.14 (5.91 to 8.63) | | |

Statistical analyses

| | |
|---|-------------------------------|
| Statistical analysis title | Statistical analysis 1 |
| Statistical analysis description: | |
| The statistical model used was a negative binomial model, including factors for treatment and type-2 diabetes at baseline, geographical region, age at baseline, estimated glomerular filtration rate at baseline, left ventricular ejection fraction at baseline, persistent or permanent atrial fibrillation at baseline, prior myocardial infarction at baseline, peripheral artery disease at baseline and smoking at baseline as covariates. The log(observation time) was used as an offset variable. | |
| Comparison groups | Placebo v Empagliflozin 10 mg |
| Number of subjects included in analysis | 6522 |
| Analysis specification | Pre-specified |
| Analysis type | other ^[3] |
| P-value | = 0.2423 |
| Method | Negative binomial regression |
| Parameter estimate | Adjusted event rate ratio |
| Point estimate | 0.87 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.68 |
| upper limit | 1.1 |

Notes:

[3] - Results are presented as Empagliflozin vs. Placebo.

Secondary: Time to cardiovascular (CV) mortality

| | |
|--|---------------------------------------|
| End point title | Time to cardiovascular (CV) mortality |
| End point description: | |
| Incidence rate of cardiovascular (CV) mortality, including deaths of unknown cause , is reported. Median time-to-event was not estimable due to insufficient events being experienced. | |
| The incidence rate was calculated as: the number of patients with a cardiovascular death event by treatment group during time at risk divided by the total time patients were at risk in that treatment group multiplied by 100 (per 100 Pt-years, Pt as abbreviation of patient). | |
| The analysis was performed on the randomised set (RS) which contained all randomised patients, whether treated or not. | |
| End point type | Secondary |
| End point timeframe: | |
| From randomisation or first study drug administration (if randomisation occurred after first drug administration), until individual day of trial completion. Up to 1004 days. | |

| | | | | |
|--|---------------------|---------------------|--|--|
| End point values | Placebo | Empagliflozin 10 mg | | |
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 3262 | 3260 | | |
| Units: Pt with events/100 pt-years at risk | | | | |
| number (confidence interval 95%) | 2.76 (2.31 to 3.25) | 2.78 (2.33 to 3.28) | | |

Statistical analyses

| | |
|---|-------------------------------|
| Statistical analysis title | Statistical analysis 1 |
| Statistical analysis description: | |
| The statistical analysis was performed using a Cox proportional hazards model with treatment, type-2 diabetes at baseline, geographical region, age at baseline, estimated glomerular filtration rate at baseline, left ventricular ejection fraction at baseline, persistent or permanent atrial fibrillation at baseline, prior myocardial infarction at baseline, peripheral artery disease at baseline and smoking at baseline as covariates. | |
| Comparison groups | Placebo v Empagliflozin 10 mg |
| Number of subjects included in analysis | 6522 |
| Analysis specification | Pre-specified |
| Analysis type | other ^[4] |
| P-value | = 0.8124 |
| Method | Regression, Cox |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 1.03 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.81 |
| upper limit | 1.31 |

Notes:

[4] - Results are presented as Empagliflozin vs. Placebo.

Secondary: Key secondary endpoint - Total number of hospitalisations for myocardial infarction (MI) or all-cause mortality

| | |
|-----------------|---|
| End point title | Key secondary endpoint - Total number of hospitalisations for myocardial infarction (MI) or all-cause mortality |
|-----------------|---|

End point description:

The total number of hospitalisations for myocardial infarction (MI) or all-cause mortality is reported using the adjusted event rate.

The adjusted event rate is based on a negative binomial model adjusted for factors for treatment and type-2 diabetes at baseline, geographical region, age at baseline, estimated glomerular filtration rate at baseline, left ventricular ejection fraction at baseline, persistent or permanent atrial fibrillation at baseline, prior myocardial infarction at baseline, peripheral artery disease at baseline and smoking at baseline as covariates. The log(observation time) was used as an offset variable.

The analysis was performed on the randomised set (RS) which contained all randomised patients, whether treated or not.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From randomisation or first study drug administration (if randomisation occurred after first drug administration), until individual day of trial completion. Up to 1004 days.

| End point values | Placebo | Empagliflozin 10 mg | | |
|---|---------------------|---------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 3262 | 3260 | | |
| Units: Events/100 patient-years at risk | | | | |
| number (confidence interval 95%) | 6.27 (5.19 to 7.58) | 6.66 (5.49 to 8.08) | | |

Statistical analyses

| Statistical analysis title | Statistical analysis 1 |
|---|-------------------------------|
| Statistical analysis description: | |
| The statistical model used was a negative binomial model, including factors for treatment and type-2 diabetes at baseline, geographical region, age at baseline, estimated glomerular filtration rate at baseline, left ventricular ejection fraction at baseline, persistent or permanent atrial fibrillation at baseline, prior myocardial infarction at baseline, peripheral artery disease at baseline and smoking at baseline as covariates. The log(observation time) was used as an offset variable. | |
| Comparison groups | Placebo v Empagliflozin 10 mg |
| Number of subjects included in analysis | 6522 |
| Analysis specification | Pre-specified |
| Analysis type | other ^[5] |
| P-value | = 0.6311 |
| Method | Negative binomial regression |
| Parameter estimate | Adjusted event rate ratio |
| Point estimate | 1.06 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.83 |
| upper limit | 1.35 |

Notes:

[5] - Results are presented as Empagliflozin vs. Placebo.

Secondary: Key secondary endpoint - Total number of non-elective all-cause hospitalisations or all-cause mortality

| | |
|--|---|
| End point title | Key secondary endpoint - Total number of non-elective all-cause hospitalisations or all-cause mortality |
| End point description: | |
| The total number of non-elective all-cause hospitalisations or all-cause mortality is reported using the adjusted event rate. | |
| The adjusted event rate is based on a negative binomial model adjusted for treatment and type-2 diabetes at baseline, geographical region, age at baseline, estimated glomerular filtration rate at baseline, left ventricular ejection fraction at baseline, persistent or permanent atrial fibrillation at baseline, prior myocardial infarction at baseline, peripheral artery disease at baseline and smoking at baseline as covariates. The log(observation time) was used as an offset variable. | |
| The analysis was performed on the randomised set (RS) which contained all randomised patients, whether treated or not. | |
| End point type | Secondary |

End point timeframe:

From randomisation or first study drug administration (if randomisation occurred after first drug administration), until individual day of trial completion. Up to 1004 days.

| End point values | Placebo | Empagliflozin 10 mg | | |
|---|------------------------|------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 3262 | 3260 | | |
| Units: Events/100 patient-years at risk | | | | |
| number (confidence interval 95%) | 26.28 (23.92 to 28.87) | 22.96 (20.84 to 25.31) | | |

Statistical analyses

| Statistical analysis title | Statistical analysis 1 |
|----------------------------|------------------------|
|----------------------------|------------------------|

Statistical analysis description:

The statistical model used was a negative binomial model, including factors for treatment and type-2 diabetes at baseline, geographical region, age at baseline, estimated glomerular filtration rate at baseline, left ventricular ejection fraction at baseline, persistent or permanent atrial fibrillation at baseline, prior myocardial infarction at baseline, peripheral artery disease at baseline and smoking at baseline as covariates. The log(observation time) was used as an offset variable.

| | |
|---|-------------------------------|
| Comparison groups | Placebo v Empagliflozin 10 mg |
| Number of subjects included in analysis | 6522 |
| Analysis specification | Pre-specified |
| Analysis type | other ^[6] |
| P-value | = 0.0463 |
| Method | Negative binomial regression |
| Parameter estimate | Adjusted event rate ratio |
| Point estimate | 0.87 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.7654 |
| upper limit | 0.9978 |

Notes:

[6] - Results are presented as Empagliflozin vs. Placebo.

Adverse events

Adverse events information^[1]

Timeframe for reporting adverse events:

From first study drug administration to last study drug administration plus 7 days (residual effect period). Up to 1004 days.

Adverse event reporting additional description:

Treated set: all patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment.

In the randomised set, the deaths due to any cause were 178 in the Placebo group and 169 in the Empagliflozin group.

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|--------------------|--------|
| Dictionary name | MedDRA |
| Dictionary version | 26.1 |

Reporting groups

| | |
|-----------------------|---------------------|
| Reporting group title | Empagliflozin 10 mg |
|-----------------------|---------------------|

Reporting group description:

Patients with an acute myocardial infarction event took, on top of standard of care, one empagliflozin (Jardiance®) 10 milligrams (mg) film-coated tablet, orally, once daily, at the same time every morning, with a glass of water.

| | |
|-----------------------|---------|
| Reporting group title | Placebo |
|-----------------------|---------|

Reporting group description:

Patients with an acute myocardial infarction event took, on top of standard of care, one placebo matching-empagliflozin 10 milligrams (mg) film-coated tablet, orally, once daily, at the same time every morning, with a glass of water.

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.

Justification: There were no subjects affect with non-serious adverse events at a rate higher than 5%. The total number of no-serious adverse events is depicted in the initial table.

| Serious adverse events | Empagliflozin 10 mg | Placebo | |
|---|------------------------|------------------------|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 765 / 3234 (23.65%) | 798 / 3229 (24.71%) | |
| number of deaths (all causes) | 165 | 175 | |
| number of deaths resulting from adverse events | 137 | 140 | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Brain neoplasm | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Acute myeloid leukaemia | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

| | | | |
|---|------------------|------------------|--|
| Adenocarcinoma | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Adenocarcinoma of colon | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 3 / 3229 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| B-cell lymphoma | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Basal cell carcinoma | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Benign neoplasm of skin | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bladder cancer | | | |
| subjects affected / exposed | 2 / 3234 (0.06%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bladder neoplasm | | | |
| subjects affected / exposed | 2 / 3234 (0.06%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Brain neoplasm malignant | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Keratoacanthoma | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac myxoma | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cervix cancer metastatic | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Cervix carcinoma | | | |
| subjects affected / exposed | 2 / 3234 (0.06%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Colon cancer | | | |
| subjects affected / exposed | 4 / 3234 (0.12%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Colon neoplasm | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Colorectal adenoma | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diffuse large B-cell lymphoma | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Endometrial cancer | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 3234 (0.00%) | 2 / 3229 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Essential thrombocythaemia | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastric cancer | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal carcinoma | | | |
| subjects affected / exposed | 2 / 3234 (0.06%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Hepatic cancer metastatic | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Breast cancer | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Large intestine benign neoplasm | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Metastatic gastric cancer | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Lung adenocarcinoma | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 2 / 3234 (0.06%) | 3 / 3229 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lung neoplasm malignant | | | |
| subjects affected / exposed | 2 / 3234 (0.06%) | 3 / 3229 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Lung squamous cell carcinoma recurrent | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Malignant melanoma | | | |
| subjects affected / exposed | 2 / 3234 (0.06%) | 3 / 3229 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Malignant neoplasm progression | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Mantle cell lymphoma | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Mesothelioma | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Metastases to liver | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 3 / 3229 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Metastases to lung | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 3234 (0.00%) | 2 / 3229 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Metastases to lymph nodes | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Metastases to peritoneum | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Metastases to pleura | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Laryngeal cancer | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Metastatic renal cell carcinoma | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Rectal adenocarcinoma | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Myelodysplastic syndrome | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Neoplasm prostate | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 3234 (0.00%) | 2 / 3229 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Neuroendocrine carcinoma | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Oesophageal carcinoma | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 2 / 3229 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Oropharyngeal neoplasm | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ovarian cancer metastatic | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Penile squamous cell carcinoma | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pharyngeal cancer | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Plasma cell myeloma | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 3 / 3229 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Plasmacytoma | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pleural neoplasm | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Prostate cancer | | | |
| subjects affected / exposed | 6 / 3234 (0.19%) | 4 / 3229 (0.12%) | |
| occurrences causally related to treatment / all | 0 / 6 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Mucoepidermoid carcinoma | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Rectal cancer | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 4 / 3229 (0.12%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal cancer | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal cell carcinoma | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Skin cancer | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Small cell lung cancer metastatic | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Soft tissue neoplasm | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Tonsil cancer metastatic | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Transitional cell carcinoma | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Rectosigmoid cancer stage III | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vascular disorders | | | |
| Arteriosclerosis | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Acute aortic syndrome | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Aortic aneurysm | | | |
| subjects affected / exposed | 3 / 3234 (0.09%) | 2 / 3229 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Aortic stenosis | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3234 (0.03%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Aortic thrombosis | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Arterial thrombosis | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Blood pressure inadequately controlled | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Jugular vein thrombosis | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Deep vein thrombosis | | | |
| subjects affected / exposed | 2 / 3234 (0.06%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Extremity necrosis | | | |
| subjects affected / exposed | 3 / 3234 (0.09%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Femoral artery embolism | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Haematoma | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3234 (0.03%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypertension | | | |
| subjects affected / exposed | 3 / 3234 (0.09%) | 3 / 3229 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypertensive crisis | | | |
| subjects affected / exposed | 7 / 3234 (0.22%) | 5 / 3229 (0.15%) | |
| occurrences causally related to treatment / all | 0 / 7 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypertensive emergency | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypertensive urgency | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypotension | | | |
| subjects affected / exposed | 8 / 3234 (0.25%) | 7 / 3229 (0.22%) | |
| occurrences causally related to treatment / all | 0 / 8 | 1 / 7 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypovolaemic shock | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Iliac artery arteriosclerosis | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Intermittent claudication | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Circulatory collapse | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 2 / 3229 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Orthostatic hypotension | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Peripheral arterial occlusive disease | | | |
| subjects affected / exposed | 2 / 3234 (0.06%) | 2 / 3229 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Peripheral artery occlusion | | | |
| subjects affected / exposed | 2 / 3234 (0.06%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Peripheral embolism | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vasoconstriction | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Subclavian artery stenosis | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Subclavian vein stenosis | | | |

| | | | |
|--|------------------|-------------------|--|
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Superficial vein thrombosis | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Peripheral ischaemia | | | |
| subjects affected / exposed | 3 / 3234 (0.09%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Surgical and medical procedures | | | |
| Hospitalisation | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| General disorders and administration site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 4 / 3229 (0.12%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Vascular stent thrombosis | | | |
| subjects affected / exposed | 3 / 3234 (0.09%) | 3 / 3229 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Chest discomfort | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Chest pain | | | |
| subjects affected / exposed | 9 / 3234 (0.28%) | 12 / 3229 (0.37%) | |
| occurrences causally related to treatment / all | 0 / 9 | 0 / 13 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |

| | | | |
|---|-------------------|-------------------|--|
| Death | | | |
| subjects affected / exposed | 21 / 3234 (0.65%) | 21 / 3229 (0.65%) | |
| occurrences causally related to treatment / all | 0 / 21 | 0 / 21 | |
| deaths causally related to treatment / all | 0 / 21 | 0 / 21 | |
| Gait disturbance | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Implant site haematoma | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 28 / 3234 (0.87%) | 27 / 3229 (0.84%) | |
| occurrences causally related to treatment / all | 1 / 33 | 0 / 31 | |
| deaths causally related to treatment / all | 0 / 2 | 0 / 0 | |
| Physical deconditioning | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pyrexia | | | |
| subjects affected / exposed | 4 / 3234 (0.12%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Sudden cardiac death | | | |
| subjects affected / exposed | 9 / 3234 (0.28%) | 7 / 3229 (0.22%) | |
| occurrences causally related to treatment / all | 0 / 9 | 0 / 7 | |
| deaths causally related to treatment / all | 0 / 9 | 0 / 7 | |
| Sudden death | | | |
| subjects affected / exposed | 11 / 3234 (0.34%) | 12 / 3229 (0.37%) | |
| occurrences causally related to treatment / all | 0 / 11 | 0 / 12 | |
| deaths causally related to treatment / all | 0 / 11 | 0 / 12 | |
| Systemic inflammatory response syndrome | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vascular stent stenosis | | | |
| subjects affected / exposed | 2 / 3234 (0.06%) | 2 / 3229 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac death | | | |
| subjects affected / exposed | 3 / 3234 (0.09%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 3 | 0 / 1 | |
| Immune system disorders | | | |
| Anaphylactic shock | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Drug hypersensitivity | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Social circumstances | | | |
| Physical assault | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Tobacco user | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Reproductive system and breast disorders | | | |
| Benign prostatic hyperplasia | | | |
| subjects affected / exposed | 2 / 3234 (0.06%) | 2 / 3229 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

| | | | |
|---|------------------|------------------|--|
| Penile scarring | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vaginal haemorrhage | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Epistaxis | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 3 / 3229 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Acute pulmonary oedema | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Acute respiratory distress syndrome | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Acute respiratory failure | | | |
| subjects affected / exposed | 6 / 3234 (0.19%) | 4 / 3229 (0.12%) | |
| occurrences causally related to treatment / all | 0 / 6 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Bronchiectasis | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bronchospasm | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |

| | | | |
|---|------------------|------------------|--|
| Chronic obstructive pulmonary disease | | | |
| subjects affected / exposed | 4 / 3234 (0.12%) | 3 / 3229 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cough | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dyspnoea | | | |
| subjects affected / exposed | 4 / 3234 (0.12%) | 5 / 3229 (0.15%) | |
| occurrences causally related to treatment / all | 1 / 4 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dyspnoea exertional | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Haemoptysis | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hiccups | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hydrothorax | | | |
| subjects affected / exposed | 2 / 3234 (0.06%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Idiopathic pulmonary fibrosis | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Obstructive sleep apnoea syndrome | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Oropharyngeal fistula | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Respiratory acidosis | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumothorax | | | |
| subjects affected / exposed | 2 / 3234 (0.06%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pulmonary congestion | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pulmonary embolism | | | |
| subjects affected / exposed | 7 / 3234 (0.22%) | 7 / 3229 (0.22%) | |
| occurrences causally related to treatment / all | 0 / 9 | 0 / 7 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pulmonary fibrosis | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 2 / 3229 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pulmonary hypertension | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 3 / 3229 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pulmonary mass | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 3234 (0.00%) | 2 / 3229 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pleural effusion | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 4 / 3229 (0.12%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Respiratory failure | | | |
| subjects affected / exposed | 5 / 3234 (0.15%) | 5 / 3229 (0.15%) | |
| occurrences causally related to treatment / all | 0 / 5 | 1 / 5 | |
| deaths causally related to treatment / all | 0 / 2 | 0 / 1 | |
| Sleep apnoea syndrome | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Psychiatric disorders | | | |
| Confusional state | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Delirium | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 2 / 3229 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Depression | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Mania | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Mental status changes | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Investigations | | | |
| Blood pressure increased | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Clostridium test positive | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatic enzyme increased | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| International normalised ratio increased | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Stress echocardiogram abnormal | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Injury, poisoning and procedural complications | | | |
| Foot fracture | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Abdominal injury | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

| | | | |
|---|------------------|------------------|--|
| Ankle fracture | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Aortic injury | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac procedure complication | | | |
| subjects affected / exposed | 3 / 3234 (0.09%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Cervical vertebral fracture | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Craniocerebral injury | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Craniofacial fracture | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 2 / 3229 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 6 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Deep vein thrombosis postoperative | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Face injury | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Fall | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 2 / 3234 (0.06%) | 5 / 3229 (0.15%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Femur fracture | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 4 / 3229 (0.12%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Head injury | | | |
| subjects affected / exposed | 2 / 3234 (0.06%) | 2 / 3229 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 1 | |
| Procedural pneumothorax | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Joint dislocation | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Limb traumatic amputation | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lower limb fracture | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lumbar vertebral fracture | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 2 / 3229 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Neck injury | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Overdose | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pelvic fracture | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumothorax traumatic | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Post procedural complication | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Post procedural haemorrhage | | | |
| subjects affected / exposed | 9 / 3234 (0.28%) | 4 / 3229 (0.12%) | |
| occurrences causally related to treatment / all | 0 / 9 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Post procedural stroke | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Postoperative delirium | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hip fracture | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3234 (0.03%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Rib fracture | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Road traffic accident | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Spinal compression fracture | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Sternal fracture | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Strangulated incisional hernia | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Subdural haematoma | | | |
| subjects affected / exposed | 2 / 3234 (0.06%) | 2 / 3229 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Surgical procedure repeated | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Thermal burn | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3234 (0.03%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Traumatic haematoma | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Upper limb fracture | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Wound dehiscence | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 2 / 3229 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Wrist fracture | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Congenital, familial and genetic disorders | | | |
| Atrial septal defect | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Buried penis syndrome | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Corneal dystrophy | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac disorders | | | |

| | | | |
|---|-------------------|-------------------|--|
| Acute coronary syndrome | | | |
| subjects affected / exposed | 5 / 3234 (0.15%) | 2 / 3229 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Acute myocardial infarction | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Angina pectoris | | | |
| subjects affected / exposed | 30 / 3234 (0.93%) | 28 / 3229 (0.87%) | |
| occurrences causally related to treatment / all | 0 / 32 | 0 / 29 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Angina unstable | | | |
| subjects affected / exposed | 52 / 3234 (1.61%) | 54 / 3229 (1.67%) | |
| occurrences causally related to treatment / all | 1 / 57 | 0 / 58 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Aortic valve stenosis | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Arrhythmia | | | |
| subjects affected / exposed | 3 / 3234 (0.09%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Arrhythmia supraventricular | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Arrhythmic storm | | | |
| subjects affected / exposed | 2 / 3234 (0.06%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Atrial fibrillation | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 18 / 3234 (0.56%) | 17 / 3229 (0.53%) | |
| occurrences causally related to treatment / all | 0 / 19 | 0 / 18 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Atrial flutter | | | |
| subjects affected / exposed | 6 / 3234 (0.19%) | 3 / 3229 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 6 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Atrial tachycardia | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Atrial thrombosis | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac arrest | | | |
| subjects affected / exposed | 11 / 3234 (0.34%) | 17 / 3229 (0.53%) | |
| occurrences causally related to treatment / all | 0 / 11 | 0 / 17 | |
| deaths causally related to treatment / all | 0 / 9 | 0 / 11 | |
| Atrioventricular block complete | | | |
| subjects affected / exposed | 3 / 3234 (0.09%) | 5 / 3229 (0.15%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bradyarrhythmia | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bradycardia | | | |
| subjects affected / exposed | 2 / 3234 (0.06%) | 5 / 3229 (0.15%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac aneurysm | | | |

| | | | |
|---|--------------------|--------------------|--|
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Atrioventricular block | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac failure | | | |
| subjects affected / exposed | 159 / 3234 (4.92%) | 230 / 3229 (7.12%) | |
| occurrences causally related to treatment / all | 1 / 194 | 2 / 306 | |
| deaths causally related to treatment / all | 0 / 17 | 0 / 23 | |
| Cardiac perforation | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac tamponade | | | |
| subjects affected / exposed | 2 / 3234 (0.06%) | 3 / 3229 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Cardiac ventricular disorder | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac ventricular thrombosis | | | |
| subjects affected / exposed | 11 / 3234 (0.34%) | 4 / 3229 (0.12%) | |
| occurrences causally related to treatment / all | 0 / 12 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardio-respiratory arrest | | | |
| subjects affected / exposed | 6 / 3234 (0.19%) | 5 / 3229 (0.15%) | |
| occurrences causally related to treatment / all | 0 / 6 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 5 | 0 / 4 | |
| Coronary artery occlusion | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 2 / 3234 (0.06%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiovascular disorder | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Chronic coronary syndrome | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Coronary artery disease | | | |
| subjects affected / exposed | 14 / 3234 (0.43%) | 14 / 3229 (0.43%) | |
| occurrences causally related to treatment / all | 0 / 14 | 0 / 14 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Coronary artery dissection | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 2 / 3229 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Coronary artery insufficiency | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Cardiogenic shock | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Coronary artery stenosis | | | |
| subjects affected / exposed | 4 / 3234 (0.12%) | 4 / 3229 (0.12%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Coronary artery thrombosis | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dilated cardiomyopathy | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dressler's syndrome | | | |
| subjects affected / exposed | 3 / 3234 (0.09%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Interventricular septum rupture | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Intracardiac thrombus | | | |
| subjects affected / exposed | 2 / 3234 (0.06%) | 3 / 3229 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Myocardial rupture | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Microvascular coronary artery disease | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 2 / 3229 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Mitral valve incompetence | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 2 / 3229 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Myocardial infarction | | | |

| | | | |
|---|--------------------|-------------------|--|
| subjects affected / exposed | 110 / 3234 (3.40%) | 94 / 3229 (2.91%) | |
| occurrences causally related to treatment / all | 0 / 119 | 0 / 104 | |
| deaths causally related to treatment / all | 0 / 20 | 0 / 10 | |
| Myocardial injury | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Myocardial ischaemia | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 6 / 3229 (0.19%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 6 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ischaemic cardiomyopathy | | | |
| subjects affected / exposed | 2 / 3234 (0.06%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nodal rhythm | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ventricle rupture | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Papillary muscle rupture | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Pericardial effusion | | | |
| subjects affected / exposed | 4 / 3234 (0.12%) | 3 / 3229 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pericardial haemorrhage | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3234 (0.03%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Pericarditis | | | |
| subjects affected / exposed | 3 / 3234 (0.09%) | 4 / 3229 (0.12%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Postinfarction angina | | | |
| subjects affected / exposed | 2 / 3234 (0.06%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Prinzmetal angina | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Sinus arrest | | | |
| subjects affected / exposed | 2 / 3234 (0.06%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Sinus bradycardia | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Sinus node dysfunction | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 3 / 3229 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Stress cardiomyopathy | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Supraventricular tachycardia | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 3 / 3234 (0.09%) | 2 / 3229 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Tachycardia | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Palpitations | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ventricular arrhythmia | | | |
| subjects affected / exposed | 3 / 3234 (0.09%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Ventricular extrasystoles | | | |
| subjects affected / exposed | 2 / 3234 (0.06%) | 2 / 3229 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ventricular fibrillation | | | |
| subjects affected / exposed | 2 / 3234 (0.06%) | 3 / 3229 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ventricular flutter | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ventricular tachycardia | | | |
| subjects affected / exposed | 18 / 3234 (0.56%) | 22 / 3229 (0.68%) | |
| occurrences causally related to treatment / all | 0 / 29 | 0 / 26 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Nervous system disorders | | | |
| Cerebral hypoperfusion | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Aphasia | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ataxia | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Carotid artery stenosis | | | |
| subjects affected / exposed | 4 / 3234 (0.12%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 1 / 5 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Carotid artery thrombosis | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cerebral haemorrhage | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cerebral infarction | | | |
| subjects affected / exposed | 6 / 3234 (0.19%) | 4 / 3229 (0.12%) | |
| occurrences causally related to treatment / all | 1 / 6 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cerebral ischaemia | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 2 / 3229 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cerebrovascular accident | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 8 / 3234 (0.25%) | 8 / 3229 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 8 | 0 / 8 | |
| deaths causally related to treatment / all | 0 / 3 | 0 / 0 | |
| Cortical laminar necrosis | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dementia | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dementia Alzheimer's type | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Intracranial mass | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Epilepsy | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 3 / 3229 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Facial paralysis | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Haemorrhage intracranial | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Haemorrhagic stroke | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Headache | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hemiparesis | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dizziness | | | |
| subjects affected / exposed | 4 / 3234 (0.12%) | 5 / 3229 (0.15%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ischaemic stroke | | | |
| subjects affected / exposed | 7 / 3234 (0.22%) | 11 / 3229 (0.34%) | |
| occurrences causally related to treatment / all | 0 / 7 | 0 / 11 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 2 | |
| Syncope | | | |
| subjects affected / exposed | 16 / 3234 (0.49%) | 19 / 3229 (0.59%) | |
| occurrences causally related to treatment / all | 2 / 18 | 1 / 19 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Lumbar radiculopathy | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Metabolic encephalopathy | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nervous system disorder | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Paraesthesia | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 2 / 3229 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Peroneal nerve palsy | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Post-traumatic epilepsy | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Presyncope | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 3 / 3229 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Radiculopathy | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ruptured cerebral aneurysm | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Seizure | | | |
| subjects affected / exposed | 2 / 3234 (0.06%) | 2 / 3229 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Status epilepticus | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Subarachnoid haemorrhage | | | |
| subjects affected / exposed | 2 / 3234 (0.06%) | 3 / 3229 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Lacunar infarction | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Transient ischaemic attack | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 2 / 3229 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vascular encephalopathy | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vertebral artery occlusion | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vertebrobasilar insufficiency | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vertebrobasilar stroke | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Tremor | | | |

| | | | |
|---|------------------|-------------------|--|
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 9 / 3234 (0.28%) | 11 / 3229 (0.34%) | |
| occurrences causally related to treatment / all | 0 / 9 | 0 / 13 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Microcytic anaemia | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 2 / 3229 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pancytopenia | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Thrombocytopenia | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Thrombocytosis | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Haemolysis | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ear and labyrinth disorders | | | |
| Sudden hearing loss | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vertigo | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 3 / 3234 (0.09%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Eye disorders | | | |
| Optic ischaemic neuropathy | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Macular hole | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diabetic retinopathy | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Macular degeneration | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Retinal artery embolism | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Retinal detachment | | | |
| subjects affected / exposed | 2 / 3234 (0.06%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Retinal infarction | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vision blurred | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Visual impairment | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal disorders | | | |
| Abdominal discomfort | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Abdominal pain | | | |
| subjects affected / exposed | 2 / 3234 (0.06%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Abdominal pain upper | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 2 / 3229 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Abdominal wall haematoma | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Colitis ischaemic | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diarrhoea | | | |
| subjects affected / exposed | 3 / 3234 (0.09%) | 5 / 3229 (0.15%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Duodenal polyp | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dyspepsia | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Enteritis | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Food poisoning | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastric ulcer | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Mechanical ileus | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal angiodysplasia | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 28 / 3234 (0.87%) | 22 / 3229 (0.68%) | |
| occurrences causally related to treatment / all | 1 / 29 | 0 / 23 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 1 | |
| Gastrointestinal necrosis | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrooesophageal reflux disease | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ileus | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ileus paralytic | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Inguinal hernia | | | |
| subjects affected / exposed | 3 / 3234 (0.09%) | 3 / 3229 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Intestinal angina | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Intestinal metaplasia | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Intestinal obstruction | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Irritable bowel syndrome | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Large intestine polyp | | | |
| subjects affected / exposed | 3 / 3234 (0.09%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastritis | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Melaena | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vomiting | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nausea | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Oesophageal stenosis | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Oesophagitis | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Oronasal fistula | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pancreatitis | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pancreatitis acute | | | |
| subjects affected / exposed | 3 / 3234 (0.09%) | 2 / 3229 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pancreatitis chronic | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pelvic floor hernia | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Rectal haemorrhage | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Rectal polyp | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Small intestinal obstruction | | | |
| subjects affected / exposed | 2 / 3234 (0.06%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Volvulus | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Mesenteric vein thrombosis | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatobiliary disorders | | | |
| Cholecystitis | | | |
| subjects affected / exposed | 2 / 3234 (0.06%) | 3 / 3229 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Cholangitis | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cholelithiasis | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cholestasis | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 2 / 3229 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Haemorrhagic cholecystitis | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatic cirrhosis | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ischaemic hepatitis | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Liver injury | | | |
| subjects affected / exposed | 6 / 3234 (0.19%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 6 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Portal vein thrombosis | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bile duct stone | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Biliary obstruction | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cholecystitis acute | | | |
| subjects affected / exposed | 2 / 3234 (0.06%) | 2 / 3229 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Skin and subcutaneous tissue disorders | | | |
| Angioedema | | | |
| subjects affected / exposed | 4 / 3234 (0.12%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dermatitis allergic | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diabetic foot | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Rash | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal and urinary disorders | | | |
| Chronic kidney disease | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 4 / 3229 (0.12%) | |
| occurrences causally related to treatment / all | 0 / 1 | 1 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Acute kidney injury | | | |
| subjects affected / exposed | 27 / 3234 (0.83%) | 43 / 3229 (1.33%) | |
| occurrences causally related to treatment / all | 6 / 32 | 8 / 51 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 4 | |
| Bladder disorder | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Calculus urinary | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cystitis haemorrhagic | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ureterolithiasis | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 2 / 3229 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Haematuria | | | |

| | | | |
|---|------------------|-------------------|--|
| subjects affected / exposed | 5 / 3234 (0.15%) | 10 / 3229 (0.31%) | |
| occurrences causally related to treatment / all | 1 / 7 | 0 / 10 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hydronephrosis | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nephritis | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nephrolithiasis | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 2 / 3229 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nephropathy toxic | | | |
| subjects affected / exposed | 6 / 3234 (0.19%) | 9 / 3229 (0.28%) | |
| occurrences causally related to treatment / all | 0 / 6 | 0 / 9 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Oliguria | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Polyuria | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal colic | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal failure | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 2 / 3234 (0.06%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 1 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal haematoma | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal impairment | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 2 / 3229 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal infarct | | | |
| subjects affected / exposed | 2 / 3234 (0.06%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dysuria | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urinary bladder polyp | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urinary retention | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 4 / 3229 (0.12%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 6 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Musculoskeletal and connective tissue disorders | | | |
| Arthritis | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Neck pain | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Chondrocalcinosis | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Intervertebral disc disorder | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Intervertebral disc protrusion | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Mobility decreased | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Muscular weakness | | | |
| subjects affected / exposed | 2 / 3234 (0.06%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Myalgia | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Back pain | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 2 / 3229 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Oligoarthritis | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pain in extremity | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Polymyalgia rheumatica | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Rotator cuff syndrome | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Spinal osteoarthritis | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Osteoarthritis | | | |
| subjects affected / exposed | 3 / 3234 (0.09%) | 3 / 3229 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infections and infestations | | | |
| Abdominal abscess | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Abscess limb | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Coronavirus infection | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Appendicitis | | | |
| subjects affected / exposed | 5 / 3234 (0.15%) | 2 / 3229 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Arthritis bacterial | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 2 / 3229 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Arthritis infective | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bacteraemia | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| COVID-19 | | | |
| subjects affected / exposed | 20 / 3234 (0.62%) | 25 / 3229 (0.77%) | |
| occurrences causally related to treatment / all | 0 / 20 | 0 / 26 | |
| deaths causally related to treatment / all | 0 / 3 | 0 / 4 | |
| COVID-19 pneumonia | | | |
| subjects affected / exposed | 14 / 3234 (0.43%) | 10 / 3229 (0.31%) | |
| occurrences causally related to treatment / all | 0 / 14 | 0 / 10 | |
| deaths causally related to treatment / all | 0 / 3 | 0 / 3 | |
| Campylobacter gastroenteritis | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cellulitis | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 3234 (0.00%) | 3 / 3229 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Clostridial infection | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Clostridium difficile infection | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Colonic abscess | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Complicated appendicitis | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Anal abscess | | | |
| subjects affected / exposed | 2 / 3234 (0.06%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 1 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Coronavirus pneumonia | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dental fistula | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Device related infection | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diabetic gangrene | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diarrhoea infectious | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diverticulitis | | | |
| subjects affected / exposed | 3 / 3234 (0.09%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Escherichia urinary tract infection | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Endotoxic shock | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Enteritis infectious | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Enterocolitis bacterial | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Epididymitis | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Erysipelas | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Escherichia sepsis | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Endocarditis | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Fungal infection | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Perineal infection | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gangrene | | | |
| subjects affected / exposed | 2 / 3234 (0.06%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastroenteritis | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastroenteritis aeromonas | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastroenteritis viral | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Herpes zoster | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infected fistula | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infection | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 2 / 3229 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Joint abscess | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Localised infection | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Neutropenic sepsis | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Norovirus infection | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ophthalmic herpes zoster | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Osteomyelitis | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Fungal skin infection | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| SARS-CoV-2 viraemia | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Respiratory tract infection | | | |
| subjects affected / exposed | 9 / 3234 (0.28%) | 8 / 3229 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 9 | 0 / 9 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Sepsis | | | |
| subjects affected / exposed | 2 / 3234 (0.06%) | 3 / 3229 (0.09%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 1 | |
| Septic shock | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 6 / 3229 (0.19%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 6 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 4 | |
| Staphylococcal bacteraemia | | | |

| | | | |
|---|-------------------|-------------------|--|
| subjects affected / exposed | 0 / 3234 (0.00%) | 2 / 3229 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Staphylococcal sepsis | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Tooth abscess | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urinary tract infection | | | |
| subjects affected / exposed | 9 / 3234 (0.28%) | 7 / 3229 (0.22%) | |
| occurrences causally related to treatment / all | 3 / 9 | 1 / 7 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Peritonitis | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumonia | | | |
| subjects affected / exposed | 31 / 3234 (0.96%) | 30 / 3229 (0.93%) | |
| occurrences causally related to treatment / all | 0 / 31 | 0 / 33 | |
| deaths causally related to treatment / all | 0 / 4 | 0 / 3 | |
| Postoperative wound infection | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 2 / 3229 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pyelonephritis | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pyelonephritis acute | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal abscess | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Salmonellosis | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urosepsis | | | |
| subjects affected / exposed | 2 / 3234 (0.06%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 2 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Viral infection | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vestibular neuronitis | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Metabolism and nutrition disorders | | | |
| Hypovolaemia | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cell death | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Decreased appetite | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dehydration | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 4 / 3229 (0.12%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diabetes mellitus | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 2 / 3229 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diabetes mellitus inadequate control | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diabetic metabolic decompensation | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hyperglycaemia | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hyperkalaemia | | | |
| subjects affected / exposed | 3 / 3234 (0.09%) | 6 / 3229 (0.19%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 6 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypocalcaemia | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypoglycaemia | | | |

| | | | |
|---|------------------|------------------|--|
| subjects affected / exposed | 3 / 3234 (0.09%) | 2 / 3229 (0.06%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypokalaemia | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hyponatraemia | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Iron deficiency | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ketoacidosis | | | |
| subjects affected / exposed | 2 / 3234 (0.06%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Metabolic acidosis | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 0 / 3229 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Polydipsia | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Type 1 diabetes mellitus | | | |
| subjects affected / exposed | 1 / 3234 (0.03%) | 1 / 3229 (0.03%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

Frequency threshold for reporting non-serious adverse events: 5 %

| Non-serious adverse events | Empagliflozin 10 mg | Placebo | |
|---|---------------------|------------------|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 0 / 3234 (0.00%) | 0 / 3229 (0.00%) | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|---------------|--|
| 20 April 2022 | This amendment introduced mainly a major change regarding the increase in the number of randomised patients. |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported